Abstract: A display device according to some embodiments includes a substrate, a first power line extending in a first direction on the substrate, and configured to transmit a first alignment signal or a first driving voltage, a second power line extending in the first direction on the substrate, and configured to transmit a second alignment signal or a second driving voltage, a first electrode extending in a second direction that is substantially perpendicular to the first direction, configured to receive the first alignment signal or the first driving voltage, and electrically connected to the first power line, a second electrode spaced apart from the first electrode, extending in the second direction, configured to receive the second alignment signal or the second driving voltage, and electrically connected to the second power line, and a light emitting element between the first electrode and the second electrode.

Abstract: The present disclosure relates to a display device, and more particularly to a display device capable of repairing transistors and an optical device including the same. According to one or more embodiments of the present disclosure, a display device including: a main pixel including a light emitting element, and a main transistor; and an auxiliary pixel adjacent to the main pixel, the auxiliary pixel including an auxiliary transistor having same characteristics as the main transistor.

Abstract: Proposed is a muscle strength-enhancing composition being capable of maintaining or strengthening muscles or preventing muscle-related diseases. More specifically, proposed is a food composition containing a composite extract as an active ingredient obtained by mixing Angelica keiskei and Morus alba L. at a weight ratio of 1:8 to 16 and extracting the resulting mixture with alcohol. The food composition promotes antioxidant activity (for example, DPPH scavenging activity and ABTS scavenging activity) and muscle function enhancement activity which suppresses muscle protein breakdown and promotes muscle building, whereby the food composition prevents muscle-related diseases by enabling muscles to be maintained or strengthened.

Abstract: An anode for a secondary battery is provided, the anode for a secondary battery including: an anode current collector; a first anode mixture layer formed on at least one surface of the anode current collector, and including a first silicon-based active material and a first conductive material; and a second anode mixture layer formed on the first anode mixture layer, and including a second silicon-based active material and a second conductive material, wherein a content of the first silicon-based active material in the first anode mixture layer is lower than a content of the second silicon-based active material in the second anode mixture layer, and a Radial Breathing Mode (RBM) peak is observed in a Raman spectrum obtained from a surface of the second anode mixture layer.

Abstract: A display device includes a first light emitting element in a first display area, a first pixel circuit in a first non-display area spaced from the first display area and connected to the first light emitting element, an insulating layer covering the first pixel circuit, a metal wiring on the insulating layer, connected to the first pixel circuit, and extending from the first non-display area to a second non-display area between the first display area and the first non-display area, and a transparent wiring on the insulating layer, connecting the first light emitting element and the metal wiring, and extending from the first display area to a surface of the metal wiring, where a trench is defined in a surface of the insulating layer in the second non-display area, and the metal wiring is in the trench in the second non-display area.

Abstract: A backlight unit includes one or more light sources operable to emit light and a light guide plate arranged adjacent to the one or more light sources, reflected lights exiting the one or more light sources via the second surfaces and entering the light guide plate. A light source includes a light emitting device having a substrate and a semiconductor stack disposed on the substrate. The reflector is structured and positioned to block light emitted from a first surface of the light emitting device by reflecting the light emitted from the first surface toward second surfaces of the light source.

Abstract: The present invention relates to an anticancer use of aristoloxazine C, and more specifically to a pharmaceutical composition and a health functional food composition which use aristoloxazine C represented by Chemical Formula 1 or an isomer or pharmaceutically acceptable salt thereof, a method for preventing, ameliorating or treating cancer by using same; and a method for isolating aristoloxazine C.

Abstract: The present invention relates to a human factor assessment method and system for autonomous driving. The human factor assessment method of autonomous driving includes generating an autonomous driving system twin based on autonomous driving system specifications and autonomous driving service logic, generating one or more human twins based on a human twin characteristic range, performing a simulation using the autonomous driving system twin and the human twin, and calculating a performance index of the autonomous driving service based on the simulation result.

Abstract: Provided is a method of manufacturing an ethylene-acrylic acid copolymer including the step of (S1) supplying an ethylene monomer and an acrylic acid comonomer to a polymerization reactor to manufacture an ethylene-acrylic acid copolymer; (S2) supplying an acrylic acid comonomer-containing mixture discharged from a front or rear end of the polymerization reactor and a cleaning solvent to a cleaning unit; and (S3) dissolving an polyacrylic acid derived from the acrylic acid comonomer contained in the mixture in the cleaning solvent. The cleaning solvent includes a polyhydric alcohol-based solvent.

Abstract: Provided are a process for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof, which is an intermediate useful for the preparation of tofacitinib, an intermediate used in the process, i.e., isopropanol solvate of methyl ((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)carbamate dibenzoyl-L-tartrate, an intermediate, having excellent stability, useful for the preparation of tofacitinib, i.e., (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine acetate, and a process for preparing tofacitinib or a pharmaceutically acceptable salt thereof.

Abstract: A cadmium-free, core shell quantum dot, a quantum dot polymer composite, and electronic devices including the quantum dot polymer composite. The core shell quantum dot has an extinction coefficient per gram of greater than or equal to 0.3, an ultraviolet-visible absorption spectrum curve that has a positive differential coefficient value at 450 nm, wherein the core shell quantum dot includes a semiconductor nanocrystal core including indium and phosphorus, and optionally zinc, and a semiconductor nanocrystal shell disposed on the semiconductor nanocrystal core, the shell including zinc, selenium, and sulfur, wherein the core shell quantum dot has a quantum efficiency of greater than or equal to about 80%, and is configured to emit green light upon excitation.

Abstract: The present invention relates to a monoclonal antibody which specifically binds to an EGF2 domain of colon cancer secreted protein-2 (CCSP-2), or an antigen-binding fragment thereof. The monoclonal antibody or the antigen-binding fragment thereof of the present invention specifically binds to the EGF2 domain of CCSP-2, and thus has significantly increased affinity compared with existing peptides specifically binding to CCSP-2 and further increased specificity compared with existing antibodies to CCSP-2. Therefore, in future, accurate diagnosis can be achieved by specific detection of CCSP-2 in the protein level.

Abstract: The present disclosure relates to a display device, and more particularly, to a display device capable of reducing or minimizing or reducing a dead space area. According to one or more embodiments of the present disclosure, a display device including: a substrate having a display area and a non-display area; a signal transmission line including a signal line in the display area of the substrate and a fan-out line extending from the signal line and in the non-display area of the substrate; and a plurality of pixels in the display area of the substrate, wherein a plurality of signal transmission lines include the signal transmission line and are respectively connected to the plurality of pixels, and the plurality of signal transmission lines are on different layers on the substrate.

Abstract: A display device includes: a substrate including first to third light emitting areas, which emit light of different colors, respectively, a light emitting element layer on the substrate and overlapping the first to third light emitting areas, a first light control pattern on the light emitting element layer and overlapping the first light emitting area, where the first light control pattern includes a first base resin and first quantum dots dispersed therein, a second light control pattern on the light emitting element layer and overlapping the second light emitting area, a third light control pattern on the light emitting element layer and overlapping the third light emitting area, and a bank layer between the first and third light control patterns and including a part inclined at an angle toward the third light control pattern. The bank layer surrounds the first, second, and third light control patterns in a plan view.

Abstract: A semiconductor nanoparticle, a method of manufacturing the semiconductor nanoparticle, and an electronic device including the nanoparticle are provided. The semiconductor nanoparticle includes silver, indium, gallium, and sulfur, wherein the semiconductor nanoparticle is configured to emit a green light, wherein the semiconductor nanoparticle has a relative mole value of zinc as defined by Equation 1 that is greater than or equal to about 0.25 and less than or equal to about 0.9: Relative ? mole ? value ? of ? zinc = [ Zn ] / ( [ Ag ] + [ In ] + [ Ga ] + [ Zn ] ) Equation ? 1 wherein, in Equation 1, [Ag], [In], [Ga], and [Zn] are molar amounts of the silver, the indium, the gallium, and the zinc in the semiconductor nanoparticle, respectively, and wherein a mole ratio of gallium to indium is greater than about 2.5:1 and less than about 5.6:1.

Abstract: The present invention relates to a novel compound which can provide a sleep improving effect or the use thereof. Some compounds have an adenosine receptor agonistic activity. The novel compound of the present invention can shorten sleep latency and extend total sleep duration, and thus may be effectively used for a pharmaceutical composition for preventing or treating a sleep disorder, a health functional food composition for preventing or relieving a sleep disorder, a composition for improving sleep, a sleep aid, or a method for treating a sleep disorder.

Abstract: A semiconductor nanoparticle including a first semiconductor nanocrystal including silver, indium, gallium, and sulfur, and a semiconductor nanoparticle including a second semiconductor nanocrystal including zinc, gallium, and sulfur, a method of manufacturing the same, and an electronic device including the same. The semiconductor nanoparticle is configured to emit a green light. The green light has a peak emission wavelength of about 500 nanometers to about 580 nanometers. In the semiconductor nanoparticle, a molar ratio of zinc to indium is about 0.1:1 to about 10:1.

Abstract: The present invention relates to a pyrrole derivative or a pharmaceutically or sitologically acceptable salt thereof, and composition for prevention, amelioration or treatment of gastrointestinal disorders comprising same as active ingredient. Through the results, it can be confirmed that the pharmacokinetic parameters, oral bioavailability and storage stability of the compound of the present invention are remarkably improved due to deuteration of the terminal methylamine moiety. The pyrrole derivative or the pharmaceutically or sitologically acceptable salt thereof the present invention exhibits excellent anticancer activity in addition to excellent proton pump inhibitory activity, and has improved pharmacokinetic parameters and chemical stability, and thus can be effectively used in the prevention, amelioration or treatment of gastrointestinal disorders, including gastric cancer.

Abstract: The present application relates to a novel promoter and a use thereof. In one embodiment of the present application, provided is a nucleic acid construct comprising a novel promoter and a transgene of the present application. At this time, on the nucleic acid construct, the novel promoter of the present application can be operably linked to the transgene.